Germline Mutations as Cancer Drug Targets
Recent studies have led to the development of novel therapeutic strategies that are redefining germline BRCA1/2, MSH2, VHL, and other alterations as therapeutically actionable. The current cost-effectiveness of high-throughput germline testing has now made it feasible to consider universal germline testing for all patients with cancer, which will ease access to an increasingly large and effective therapeutic portfolio.
Authors
- Tin‐Yun Tang (ORCID: https://orcid.org/0000-0003-2030-9518)
- Karen Colbert Maresso (ORCID: https://orcid.org/0009-0005-4972-9016)
- Eduardo Vilar (ORCID: https://orcid.org/0000-0001-6404-3761)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Joanne Ngeow (ORCID: https://orcid.org/0000-0003-1558-3627)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Nanyang Technological University (SG)
- National Cancer Centre Singapore (SG)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-1241
- Citations
- 2
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.63